SCHEMBL6829337

SCHEMBL6829337

COC(=O)c1ccc(N)cc1OCCO

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.55
CYP1A2 P05177 3/20 0.52
CYP2D6 P10635 2/20 0.52
SCN1A P35498 1/20 0.52
SCN2A Q99250 1/20 0.52
SCN3A Q9NY46 1/20 0.52
ALDH1A1 P00352 5/20 0.47
TDP1 Q9NUW8 1/20 0.46
KDM4E B2RXH2 5/20 0.44
MAPT P10636 5/20 0.44
HSD17B10 Q99714 3/20 0.44
HPGD P15428 3/20 0.44
GLA P06280 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
ATM Q13315 1/20 0.44
ABL1 P00519 1/20 0.43
HSP90AA1 P07900 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26985201 0.88 GAA (0.55) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL15295021 0.88 CYP1A2 (0.59) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL2124146 0.87 GAA (0.54) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL2337419 0.84 TDP1 (0.62) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL8398812 0.83 KDM4E (0.53) GAAALDH1A1TDP1KDM4EMAPT
SCHEMBL25491034 0.83 ALDH1A1 (0.60) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL1734232 0.82 CYP2D6 (0.73) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL20562059 0.82 SLC6A3 (0.50) GAACYP1A2CYP2D6ALDH1A1TDP1
SCHEMBL479421 0.82 GAA (0.55) GAACYP1A2CYP2D6SCN1ASCN2A
SCHEMBL224165 0.80 ALDH1A1 (0.71) GAAALDH1A1KDM4EMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004046118-A2 2-4-(DI-PHENYL-AMINO)-PYRIMIDINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS BAYER PHARMACEUTICALS CORPORATION (US) 2004-06-03 WO disclosed